NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today presented data from a Phase IV study evaluating the effects of Bystolic® (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension (ASH). Results showed Bystolic significantly reduced sitting systolic (p=0.001) and diastolic (p<0.0001) blood pressure (BP) when used as monotherapy and was well tolerated. Bystolic is a beta blocker approved by the U.S. Food and Drug Administration for the treatment of mild to moderate hypertension and can be used alone or in combination with other antihypertensive treatments.
